Corticosteroids to Treat Pancreatitis
Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study
Beth Israel Deaconess Medical Center
86 participants
Mar 6, 2022
INTERVENTIONAL
Conditions
Summary
This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.
Eligibility
Inclusion Criteria4
- Adult (≥18 years)
- Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.
- Admission or planned admission to an intensive care unit
- SOFA disease severity score ≥3 (or at least 3 points above a known baseline)
Exclusion Criteria5
- Known diagnosis of autoimmune pancreatitis
- Existing clinical indication for corticosteroids at a dose \>5mg of oral prednisone daily (or equivalent)
- Contraindication to receiving corticosteroids
- Protected populations (prisoners)
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hydrocortisone is a steroid (corticosteroid) medication.
50ml of 0.9% NACL will serve as the placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05160506